Nucleic Acid Therapy for β-Thalassemia

References

• Cao A, Galanello R. Beta-thalassemia. Genet Med. 2010;12(2):61–76. doi:10.1097/GIM.0b013e3181cd68ed20098328
   PubMed Web of Science ®Google Scholar
• Cao A, Kan YW. The prevention of Thalassemia. Cold Spring Harb Perspect Med. 2013;3(2):a011775. doi:10.1101/cshperspect.a01177523378598
   PubMed Web of Science ®Google Scholar
• Rivella S. Ineffective erythropoiesis and Thalassemias. Curr Opin Hematol. 2009;16(3):187–194. doi:10.1097/MOH.0b013e32832990a419318943
   PubMed Web of Science ®Google Scholar
• Nienhuis AW, Nathan DG. Pathophysiology and clinical manifestations of the β-thalassemias. Cold Spring Harb Perspect Med. 2012;2:12. doi:10.1101/cshperspect.a011726
   Web of Science ®Google Scholar
• Riewpaiboon A, Nuchprayoon I, Torcharus K, et al. Economic burden of Beta-thalassemia/Hb E and Beta-thalassemia major in Thai children. BMC Res Notes. 2010;3(1):29. doi:10.1186/1756-0500-3-2920181056
   PubMedGoogle Scholar
• Ansari S, Baghersalimi A, Azarkeivan A, et al. Quality of life in patients with Thalassemia major. Iran J Ped Hematol Oncol. 2014;4(2):57–63.25002926
   PubMedGoogle Scholar
• Kleanthous M, Phylactides M. Thalassemia and its relevance to personalized medicine. Per Med. 2008;5(2):141–153. doi:10.2217/17410541.5.2.14129783353
   PubMedGoogle Scholar
• Fucharoen S. Overview of genotypes and Phenotypes of Thalassemia in Asia Availabe from: https://www.slideshare.net/Thalassaemia_Intl_Fed/overview-of-genotypes-and-phenotypes-of-thalassemia-inasia. Accessed September 5, 2020.
   Google Scholar
• Thein SL. Molecular basis of β-thalassemia and potential therapeutic targets. Blood Cells Mol Dis. 2017.
   PubMed Web of Science ®Google Scholar
• Voon HPJ, Wardan H, Vadolas J. Co-inheritance of α- and β-thalassaemia in mice ameliorates thalassaemic phenotype. Blood Cells Mol Dis. 2007;39(2):184–188. doi:10.1016/j.bcmd.2007.01.00617493845
   PubMedGoogle Scholar
• Mettananda S, Gibbons RJ, Higgs DR. α-globin as a molecular target in treatment of β-thalassemia. Blood. 2015;125:3694–3701. doi:10.1182/blood-2015-03-63359425869286
   PubMed Web of Science ®Google Scholar
• Voon HPJ, Wardan H, Vadolas J. siRNA-mediated reduction of α-globin results in phenotypic improvements in β-thalassemic cells. Haematologica. 2008;93(8):1238–1242. doi:10.3324/haematol.1255518556409
   PubMedGoogle Scholar
• Sarakul O, Vattanaviboon P, Wilairat P, et al. Inhibition of α-globin gene expression by RNAi. Biochem Biophys Res Commun. 2008;369(3):935–938. doi:10.1016/j.bbrc.2008.02.12418328259
   PubMedGoogle Scholar
• Xie S-Y, Ren Z-R, Zhang J-Z, et al. Restoration of the balanced α/β-globin gene expression in β 654 -thalassemia mice using combined RNAi and antisense RNA approach. Hum Mol Genet. 2007;16(21):2616–2625. doi:10.1093/hmg/ddm21817716993
   PubMedGoogle Scholar
• Xie SY, Li W, Ren ZR, et al. Correction of β654-thalassaemia mice using direct intravenous injection of siRNA and antisense RNA vectors. Int J Hematol. 2011;93(3):301–310. doi:10.1007/s12185-010-0727-121369857
   PubMedGoogle Scholar
• Mettananda S, Fisher CA, Hay D, et al. Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia. Nat Commun. 2017;8(1):424. doi:10.1038/s41467-017-00479-728871148
   PubMedGoogle Scholar
• Valencia-Sanchez MA, Liu J, Hannon GJ, et al. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20(5):515–524. doi:10.1101/gad.139980616510870
   PubMed Web of Science ®Google Scholar
• Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet. 2009;10(2):94–108.19148191
   PubMed Web of Science ®Google Scholar
• Li H, Yang Y, Hong W, et al. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Tar. 2020;5(1):1.
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human thalassaemia. Nature. 2010;467(7313):318–322. doi:10.1038/nature0932820844535
   PubMed Web of Science ®Google Scholar
• Negre O, Eggimann A-V, Beuzard Y, et al. Gene therapy of the β-hemoglobinopathies by lentiviral transfer of the β(A(T87Q))-globin gene. Hum Gene Ther. 2016;27(2):148–165. doi:10.1089/hum.2016.00726886832
   PubMed Web of Science ®Google Scholar
• Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018;378(16):1479–1493. doi:10.1056/NEJMoa170534229669226
   PubMed Web of Science ®Google Scholar
• Schuessler-Lenz M, Enzmann H, Vamvakas S. Regulators’ advice can make a difference: european medicines agency approval of zynteglo for beta thalassemia. Clin Pharmacol Ther. 2020;107(3):492–494. doi:10.1002/cpt.163931705534
   PubMedGoogle Scholar
• Miccio A, Cesari R, Lotti F, et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of β-thalassemia. Proc Natl Acad Sci USA. 2008;105(30):10547–10552. doi:10.1073/pnas.071166610518650378
   PubMed Web of Science ®Google Scholar
• Marktel S, Cicalese MP, Giglio F, et al. Gene therapy for Beta thalassemia: preliminary results from the PHASE I/II TIGET-BTHAL trial of autologous hematopoietic stem cells genetically modified with globe lentiviral vector. Blood. 2017;130(Suppl 1):355.
   Google Scholar
• Marktel S, Scaramuzza S, Cicalese MP, et al. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia. Nat Med. 2019;25(2):234–241. doi:10.1038/s41591-018-0301-630664781
   PubMed Web of Science ®Google Scholar
• Fucharoen S, Weatherall DJ. The hemoglobin E thalassemias. Cold Spring Harb Perspect Med. 2012;2:8. doi:10.1101/cshperspect.a011734
   Web of Science ®Google Scholar
• Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11:125. doi:10.1038/nrd362522262036
   PubMed Web of Science ®Google Scholar
• Havens MA, Hastings ML. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016;44(14):6549–6563. doi:10.1093/nar/gkw53327288447
   PubMed Web of Science ®Google Scholar
• Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta. 1999;1489(1):141–158. doi:10.1016/S0167-4781(99)00150-510807004
   PubMed Web of Science ®Google Scholar
• Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2018;14(1):9–21.29192260
   PubMed Web of Science ®Google Scholar
• Crooke ST, Vickers TA, Liang X-H. Phosphorothioate modified oligonucleotide-protein interactions. Nucleic Acids Res. 2020;48(10):5235–5253. doi:10.1093/nar/gkaa29932356888
   PubMedGoogle Scholar
• Svasti S, Suwanmanee T, Fucharoen S, et al. RNA repair restores hemoglobin expression in IVS2–654 thalassemic mice. Proc Natl Acad Sci USA. 2009;106(4):1205–1210. doi:10.1073/pnas.081243610619164558
   PubMed Web of Science ®Google Scholar
• El-Beshlawy A, Mostafa A, Youssry I, et al. Correction of aberrant pre-mRNA splicing by antisense oligonucleotides in β-thalassemia Egyptian patients with IVSI-110 mutation. J Pediatr Hematol Oncol. 2008;30(4):281–284. doi:10.1097/MPH.0b013e3181639afe18391696
   PubMedGoogle Scholar
• Derakhshan SM, Khaniani MS. Restoration of correct splicing in IVSI-110 mutation of β-globin gene with antisense oligonucleotides: implications and applications in functional assay development. Iran J Basic Med Sci. 2017;20(6):700–707. doi:10.22038/IJBMS.2017.884028868125
   PubMedGoogle Scholar
• Suwanmanee T, Sierakowska H, Lacerra G, et al. Restoration of human β-globin gene expression in murine and human IVS2–654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. Mol Pharmacol. 2002;62(3):545–553. doi:10.1124/mol.62.3.54512181431
   PubMed Web of Science ®Google Scholar
• Nualkaew T, Jearawiriyapaisarn N, Hongeng S, et al. Restoration of correct βIVS2−654-globin mRNA splicing and HbA production by engineered U7 snRNA in β-thalassaemia/HbE erythroid cells. Sci Rep. 2019;9(1):7672. doi:10.1038/s41598-019-43964-331113996
   PubMedGoogle Scholar
• Phanthong P, Borwornpinyo S, Kitiyanant N, et al. Enhancement of β‐globin gene expression in thalassemic IVS2‐654 induced pluripotent stem cell‐derived erythroid cells by modified U7 snRNA. Stem Cells Transl Med. 2017;6(4):1059–1069. doi:10.1002/sctm.16-012128213976
   PubMedGoogle Scholar
• Schmajuk G, Sierakowska H, Kole R. Antisense oligonucleotides with different backbones: modification of splicing pathways and efficacy of uptake. J Biol Chem. 1999;274(31):21783–21789. doi:10.1074/jbc.274.31.2178310419493
   PubMed Web of Science ®Google Scholar
• Lacerra G, Sierakowska H, Carestia C, et al. Restoration of Hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci USA. 2000;97(17):9591–9596. doi:10.1073/pnas.97.17.959110944225
   PubMedGoogle Scholar
• Preedagasamzin S, Nualkaew T, Pongrujikorn T, et al. Engineered U7 snRNA mediates sustained splicing correction in erythroid cells from β-thalassemia/HbE patients. Biochem Biophys Res Commun. 2018;499(1):86–92. doi:10.1016/j.bbrc.2018.03.10229550480
   PubMedGoogle Scholar
• Hammond SM, Wood MJA. Genetic therapies for RNA mis-splicing diseases. Trends Genet. 2011;27(5):196–205. doi:10.1016/j.tig.2011.02.00421497936
   PubMed Web of Science ®Google Scholar
• Gorman L, Suter D, Emerick V, et al. Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc Natl Acad Sci U S A. 1998;95:4929–4934. doi:10.1073/pnas.95.9.49299560205
   PubMed Web of Science ®Google Scholar
• Suter D, Tomasini R, Reber U, et al. Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human β-thalassemic mutations. Hum Mol Genet. 1999;8(13):2415–2423. doi:10.1093/hmg/8.13.241510556289
   PubMedGoogle Scholar
• Vacek MM, Ma H, Gemignani F, et al. High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA. Blood. 2003;101(1):104–111. doi:10.1182/blood-2002-06-186912393543
   PubMedGoogle Scholar
• Eckenfelder A, Tordo J, Babbs A, et al. The cellular processing capacity limits the amounts of chimeric U7 snRNA available for antisense delivery. Mol Ther Nucleic Acids. 2012;1:e31. doi:10.1038/mtna.2012.2423344083
   PubMedGoogle Scholar
• Goyenvalle A, Babbs A, van Ommen G-JB, et al. Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: promising tool for DMD therapy. Mol Ther. 2009;17(7):1234–1240. doi:10.1038/mt.2009.11319455105
   PubMed Web of Science ®Google Scholar
• Goyenvalle A, Wright J, Babbs A, et al. Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy. Mol Ther. 2012;20(6):1212–1221. doi:10.1038/mt.2012.2622354379
   PubMed Web of Science ®Google Scholar
• Imbert M, Dias-Florencio G, Goyenvalle A. Viral vector-mediated antisense therapy for genetic diseases. Genes. 2017;8(2):51. doi:10.3390/genes8020051
   PubMed Web of Science ®Google Scholar
• Madocsai C, Lim SR, Geib T, et al. Correction of SMN2 pre-mRNA splicing by antisense U7 small nuclear RNAs. Mol Ther. 2005;12(6):1013–1022. doi:10.1016/j.ymthe.2005.08.02216226920
   PubMedGoogle Scholar
• Meyer K, Marquis J, Trüb J, et al. Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum Mol Genet. 2008;18(3):546–555. doi:10.1093/hmg/ddn38219010792
   PubMedGoogle Scholar
• Odermatt P, Trüb J, Furrer L, et al. Somatic therapy of a mouse SMA model with a U7 snRNA gene correcting SMN2 splicing. Mol Ther. 2016;24(10):1797–1805. doi:10.1038/mt.2016.15227456062
   PubMedGoogle Scholar
• De Angelis FG, Sthandier O, Berarducci B, et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Δ48-50 DMD cells. Proc Natl Acad Sci USA. 2002;99(14):9456–9461. doi:10.1073/pnas.14230229912077324
   PubMed Web of Science ®Google Scholar
• Fang Y, Chen X, Godbey WT. Chapter 42 - Gene editing in regenerative medicine In: Atala A, Lanza R, Mikos AG, Nerem R, editors. Principles of Regenerative Medicine. Third Edition Boston: Academic Press; 2019:741–759.
   Google Scholar
• Gupta RM, Musunuru K. Expanding the genetic editing tool kit: zFNs, TALENs, and CRISPR-Cas9. J Clin Invest. 2014;124(10):4154–4161. doi:10.1172/JCI7299225271723
   PubMed Web of Science ®Google Scholar
• Carroll D. Genome engineering with zinc-finger nucleases. Genetics. 2011;188(4):773–782. doi:10.1534/genetics.111.13143321828278
   PubMed Web of Science ®Google Scholar
• Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Mol Ther. 2016;24(3):430–446. doi:10.1038/mt.2016.1026755333
   PubMed Web of Science ®Google Scholar
• Modares Sadeghi M, Shariati L, Hejazi Z, et al. Inducing indel mutation in the SOX6 gene by zinc finger nuclease for gamma reactivation: an approach towards gene therapy of Beta-thalassemia. J Cell Biochem. 2018;119(3):2512–2519. doi:10.1002/jcb.2641228941328
   PubMedGoogle Scholar
• Xu P, Tong Y, Liu X-Z, et al. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2–654 (C > T) mutation in β-thalassemia-derived iPSCs. Sci Rep. 2015;5:12065. doi:10.1038/srep1206526156589
   PubMed Web of Science ®Google Scholar
• Fang Y, Cheng Y, Lu D, et al. Treatment of β654-thalassaemia by TALENs in a mouse model. Cell Prolif. 2018;51(6):e12491. doi:10.1111/cpr.1249130070404
   PubMedGoogle Scholar
• Bolotin A, Quinquis B, Sorokin A, et al. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology. 2005;151(8):2551–2561. doi:10.1099/mic.0.28048-016079334
   PubMedGoogle Scholar
• Brouns SJJ, Jore MM, Lundgren M, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science. 2008;321(5891):960–964. doi:10.1126/science.115968918703739
   PubMed Web of Science ®Google Scholar
• Ran FA, Hsu PD, Wright J, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protocols. 2013;8(11):2281–2308. doi:10.1038/nprot.2013.14324157548
   PubMed Web of Science ®Google Scholar
• Guan Y, Ma Y, Li Q, et al. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates Hemophilia in mouse. EMBO Mol Med. 2016;8(5):477–488. doi:10.15252/emmm.20150603926964564
   PubMed Web of Science ®Google Scholar
• Liang X, Potter J, Kumar S, et al. Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA. J Biotechnol. 2017;241:136–146. doi:10.1016/j.jbiotec.2016.11.01127845164
   PubMed Web of Science ®Google Scholar
• Xie N, Zhou Y, Sun Q, et al. Novel epigenetic techniques provided by the CRISPR/Cas9 system. Stem Cells Int. 2018;2018:7834175. doi:10.1155/2018/783417530123293
   PubMedGoogle Scholar
• Yang F, Liu C, Chen D, et al. CRISPR/Cas9-loxP-mediated gene editing as a novel site-specific genetic manipulation tool. Mol Ther Nucleic Acids. 2017;7:378–386. doi:10.1016/j.omtn.2017.04.01828624213
   PubMedGoogle Scholar
• Miano JM, Zhu QM, Lowenstein CJ. A CRISPR path to engineering new genetic mouse models for cardiovascular research. Arterioscler Thromb Vasc Biol. 2016;36(6):1058–1075. doi:10.1161/ATVBAHA.116.30479027102963
   PubMedGoogle Scholar
• Xie F, Ye L, Chang JC, et al. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res. 2014;24:1526–1533. doi:10.1101/gr.173427.11425096406
   PubMed Web of Science ®Google Scholar
• Antony JS, Latifi N, Haque AKMA, et al. Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors. Mol Cell Pediatr. 2018;5(1):9. doi:10.1186/s40348-018-0086-130430274
   PubMedGoogle Scholar
• Wattanapanitch M, Damkham N, Potirat P, et al. One-step genetic correction of hemoglobin E/Beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system. Stem Cell Res Ther. 2018;9(1):46. doi:10.1186/s13287-018-0779-329482624
   PubMedGoogle Scholar
• Liu Y, Yang Y, Kang X, et al. One-Step biallelic and scarless correction of a β-Thalassemia mutation in patient-specific iPSCs without drug selection. Mol Ther Nucleic Acids. 2017;6:57–67. doi:10.1016/j.omtn.2016.11.01028325300
   PubMedGoogle Scholar
• Xu S, Luk K, Yao Q, et al. Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia. Blood. 2019;133(21):2255–2262. doi:10.1182/blood-2019-01-89509430704988
   PubMedGoogle Scholar
• Kouranova E, Forbes K, Zhao G, et al. CRISPRs for optimal targeting: delivery of CRISPR components as DNA, RNA, and protein into cultured cells and single-cell embryos. Hum Gene Ther. 2016;27(6):464–475. doi:10.1089/hum.2016.00927094534
   PubMed Web of Science ®Google Scholar
• Lino CA, Harper JC, Carney JP, et al. Delivering CRISPR: A review of the challenges and approaches. Drug Deliv. 2018;25(1):1234–1257. doi:10.1080/10717544.2018.147496429801422
   PubMed Web of Science ®Google Scholar
• Yu X, Liang X, Xie H, et al. Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX. Biotechnol Lett. 2016;38(6):919–929. doi:10.1007/s10529-016-2064-926892225
   PubMedGoogle Scholar
• Li G, Zhang X, Zhong C, et al. Small molecules enhance CRISPR/Cas9-mediated homology-directed genome editing in primary cells. Sci Rep. 2017;7(1):8943. doi:10.1038/s41598-017-09306-x28827551
   PubMedGoogle Scholar
• Thein SL. The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med. 2013;3:5. doi:10.1101/cshperspect.a011700
   Web of Science ®Google Scholar
• Kaufman DP, Khattar J, Lappin SL. Physiology, Fetal Hemoglobin. Treasure Island (FL). StatPearls Publishing; 2020.
   Google Scholar
• Lohani N, Bhargava N, Munshi A, et al. Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders. J Cell Physiol. 2018;233(6):4563–4577. doi:10.1002/jcp.2629229159826
   PubMed Web of Science ®Google Scholar
• Bianchi N, Zuccato C, Lampronti I, et al. Fetal hemoglobin inducers from the natural world: A novel approach for identification of drugs for the treatment of β-thalassemia and sickle-cell anemia. Evidence-Based Complementary and Alternative Med. 2009;6(2):141–151. doi:10.1093/ecam/nem139
   PubMed Web of Science ®Google Scholar
• Taghavi SA, Hosseini KM, Tamaddon G, et al. Inhibition of γ/β globin gene switching in CD 34+ derived erythroid cells by BCL11A RNA silencing. Indian J Hematol Blo. 2019;35(4):758–764. doi:10.1007/s12288-019-01131-8
   PubMed Web of Science ®Google Scholar
• Guda S, Brendel C, Renella R, et al. miRNA-embedded shRNAs for lineage-specific BCL11A knockdown and hemoglobin F induction. Mol Ther. 2015;23(9):1465–1474. doi:10.1038/mt.2015.11326080908
   PubMed Web of Science ®Google Scholar
• Brendel C, Guda S, Renella R, et al. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. J Clin Inves. 2016;126(10):3868–3878. doi:10.1172/JCI87885
   PubMed Web of Science ®Google Scholar
• Hu JH, Navas P, Cao H, et al. Systematic RNAi studies on the role of Sp/KLF factors in globin gene expression and erythroid differentiation. J Mol Biol. 2007;366(4):1064–1073. doi:10.1016/j.jmb.2006.12.04717224162
   PubMedGoogle Scholar
• Roosjen M, McColl B, Kao B, et al. Transcriptional regulators Myb and BCL11A interplay with DNA methyltransferase 1 in developmental silencing of embryonic and fetal β-like globin genes. FASEB J. 2014;28(4):1610–1620. doi:10.1096/fj.13-24266924371119
   PubMedGoogle Scholar
• Khosravi MA, Abbasalipour M, Concordet JP, et al. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease. Eur J Pharmacol. 2019;854:398–405.31039344
   PubMed Web of Science ®Google Scholar
• Psatha N, Reik A, Phelps S, et al. Disruption of the BCL11A erythroid enhancer reactivates fetal hemoglobin in erythroid cells of patients with β-thalassemia major. Mol Ther- Meth Clin D. 2018;10:313–326. doi:10.1016/j.omtm.2018.08.003
   PubMed Web of Science ®Google Scholar
• Chang K-H, Smith SE, Sullivan T, et al. Long-term engraftment and fetal globin induction upon BCL11A gene editing in bone-marrow-derived CD34(+) hematopoietic stem and progenitor cells. Molecular Therapy Methods Clinical Development. 2017;4:137–148. doi:10.1016/j.omtm.2016.12.00928344999
   PubMed Web of Science ®Google Scholar
• Shariati L, Khanahmad H, Salehi M, et al. Genetic disruption of the KLF1 gene to overexpress the γ-globin gene using the CRISPR/Cas9 system. J Gene Med. 2016;18(10):294–301. doi:10.1002/jgm.292827668420
   PubMed Web of Science ®Google Scholar
• Lamsfus-Calle A, Daniel-Moreno A, Antony JS, et al. Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34+ HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin. Sci Rep. 2020;10(1):10133. doi:10.1038/s41598-020-66309-x32576837
   PubMedGoogle Scholar
• Liu N, Hargreaves VV, Zhu Q, et al. Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch. Cell. 2018;173(2):430–42.e17. doi:10.1016/j.cell.2018.03.01629606353
   PubMed Web of Science ®Google Scholar
• Weber L, Frati G, Felix T, et al. Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype. Sci Adv. 2020;6(7):eaay9392. doi:10.1126/sciadv.aay939232917636
   PubMed Web of Science ®Google Scholar
• Zhan J, Irudayam MJ, Nakamura Y, et al. High level of fetal-globin reactivation by designed transcriptional activator-like effector. Blood Adv. 2020;4(4):687–695. doi:10.1182/bloodadvances.201900048232084259
   PubMedGoogle Scholar
• Métais JY, Doerfler PA, Mayuranathan T, et al. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Adv. 2019;3(21):3379–3392. doi:10.1182/bloodadvances.201900082031698466
   PubMedGoogle Scholar
• ClinicalTrials. A safety and efficacy study evaluating CTX001 in subjects with transfusion-dependent β-thalassemia; 2018 Available from: https://clinicaltrials.gov/ct2/show/NCT03655678. Accessed 824, 2020.
   Google Scholar